I was awarded a BSc (Hons) from Manchester University (2007) in Medical Biochemistry and as part of this programme of study undertook a year placement at KuDOS Pharmaceuticals, investigating potential biomarkers to predict response to PARP-1 inhibitors, using proteomics. In 2007 I joined the lab of Prof Barbara Durkacz in the drug discovery team at the Northern Institute for Cancer Research for her PhD studies looking at how PARP-1 regulates NF-kB following DNA damage and TNF-alpha.

In 2011, I joined the lab of Prof Neil Perkins and have developed an interest in the role of RelA and c-Rel in the response to oncogene-induced replication stress. My postdoctoral work has focused on developing in vivo models within the group, with my main interest being in hematological malignancies, in particular B-cell lymphoma.

• Hunter JE, Willmore E, Irving JAE, Hostomsky Z, Veuger SJ, Durkacz BW. NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene 2012, 31(2), 251-264.
• Tudhope SJ, Mulligan EA, Hunter JE, Summerfield GP, Marshall S, Wallis J, Marr H, Evans P, Lowe C, Durkacz BW, Zhang J, Meshulam J, Bobb K, Willmore E. P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Moles A, Butterworth JA, Sanchez A, Hunter JE, Leslie J, Sellier H, Tiniakos D, Cockell SJ, Mann DA, Oakley F, Perkins ND. A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-kB dependent liver regeneration and cancer. Oncogene 2016, 35(35), 4623-4632.
• Hunter JE, Leslie J, Perkins ND. c-Rel and its many roles in cancer: an old story with new twists. British Journal of Cancer 2016, 114(1), 1-6.
• Walton MI, Eve PD, Hayes A, Henley AT, Valenti MR, Brandon AKD, Box G, Boxall KJ, Tall M, Swales K, Matthews TP, McHardy T, Lainchbury M, Osborne J, Hunter JE, Perkins ND, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Collins I, Garrett MD. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma. Oncotarget 2016, 7(3), 2329-2342.
• Hunter JE, Butterworth JA, Zhao B, Sellier H, Campbell KJ, Thomas HD, Bacon CM, Cockell SJ, Gewurz BE, Perkins ND. The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma. Oncogene 2016, 35(26), 3476-3484.
• Willmore E, Gardner A, Tudhope S, Murtani B, Caffry J, Mulligan E, Hunter J, Wallis J, Marr H, Beretta G, Breen D, Paul A, Edwards D, Young L, Suckling C, Plevin R, Boyd M, Mackay S, Perkins N. Novel small molecule IKK alpha inhibitors inhibit non- canonical NF-kappa B signaling and survival of primary CLL cells. In: XVI International Workshop on Chronic Lymphocytic Leukemia. 2015, Sydney, Australia: Taylor & Francis.
• Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patternson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia. Oncotarget 2015, 6(41), 43978-43991.
• Moles A, Butterworth J, Hunter JE, Sanchez AM, Tiniakos D, Mann D, Oakley F, Perkins ND. Thr505 RelA phosphorylation controls liver proliferative response and supresses NF-kappa B tumor-promoting activities. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015. 2015, San Francisco, California: John Wiley & Sons, Inc.
• Tavora B, Reynolds LE, Batista S, Demircioglu F, Fernandez I, Lechertier T, Lees DM, Wong PP, Alexopoulou A, Elia G, Clear A, Ledoux A, Hunter J, Perkins N, Gribben JG, Hodivala-Dilke KM. Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature 2014, 514(7520), 112-116.
• Hunter JE, Butterworth J, Perkins ND, Bateson M, Richardson CA. Using body temperature, food and water consumption as biomarkers of disease progression in mice with Eμ-myc lymphoma. British Journal of Cancer 2014, 110, 928-934.
• Moles A, Butterworth J, Hunter J, Sanchez A, Mann D, Oakley F, Perkins ND. Mutation of Rela THR505 Enhances Liver Regeneration Following Partial Hepatectomy. In: 50th The International Liver Congress 2015. 2015, Vienna, Austria: Elsevier.